MaxCyte, Inc. Common Stock
$1.18
Market Cap
$121.78M
Shares Outstanding
103.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 5, 2019
Round Lot
100
Locale
US
Day Open
$1.20
Day High
$1.23
Day Low
$1.17
Volume
299.5K
VWAP
$1.20
Prev Close
$1.19
Transactions
--
Acc. Volume
--
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
MaxCyte, Inc. Common Stock (MXCT) closed the 2026-09-16 session at $1.18, down 0.84% versus the previous close (-0.01). The stock opened at $1.20 and traded between $1.17 and $1.23 during that session. Session trading volume was 299K shares. The volume-weighted average price (VWAP) is $1.20.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
MaxCyte, Inc. Common Stock has a market capitalization of $121.8 million. The company operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry classification. MXCT is listed on the XNAS exchange. The company employs approximately 91 people. MaxCyte, Inc. Common Stock is headquartered in ROCKVILLE, MD. The recorded listing date is 2019-12-05.
On this page you can find market MXCT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector.